Modern mucosal vaccines, adjuvants and microbicides

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 1, 2009, Pages 21-23

  Cranage, Martin P ^a   Manoussaka, Maria ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Conference; Microbicide; Mucosal adjuvant; Mucosal immune response; Mucosal vaccine; Route of delivery; Safety

Indexed keywords

BACTERIAL VACCINE; CD4 ANTIGEN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; FLAGELLIN; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MICROBICIDE; ORAL POLIOMYELITIS VACCINE; PEPTIDE VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT VIRUS ENVELOPE PROTEIN; ROTAVIRUS VACCINE; TENOFOVIR; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 5 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG COST; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; INFLUENZA; MUCOSAL DRUG ADMINISTRATION; NONHUMAN; VACCINATION; VACCINE PRODUCTION; VAGINA RING; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL VACCINES; HUMANS; IMMUNITY, MUCOSAL; MICE; MUCOUS MEMBRANE; VACCINATION; VACCINES; VIRAL VACCINES;

EID: 69449089350     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.1.21     Document Type: Conference Paper

References (12)

1. Van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000).
2. Mutsch M, Zhou W, Rhodes P et al. Use of inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004).
3. Frech SA, Kenney RT, Spyr CA et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 23, 946-950 (2005).
4. Song J-H, Nguyen HH, Cuburu N et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 105, 1644-1649 (2008).
5. Hinkula J, Devito C, Zuber B et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 24, 4494-4497 (2006).
6. Buonaguro L, Devito C, Tornesello ML et al. DNA-VLP prime-boost intranasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25, 5968-5977 (2007).
7. Cranage M, Sharpe S, Herrera C et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5(8), E157 (2008).
8. Chang TL-Y, Chang C-H, Simpson DA et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl Acad. Sci. USA 100, 11672-11677 (2003).
9. Liu X, Lagenaur LA, Simpson DA et al. Engineering vaginal Lactobaccillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50, 3250-3259 (2006).
10. Nochi T, Takagi H, Yuki Y et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl Acad. Sci. USA 104, 10986-10991 (2007).
11. Nochi T, Yuki Y, Matsumura A et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J. Exp. Med. 204, 2789-2796 (2007).
12. Lavelle EC. Lectins and microparticles for enhanced oral vaccination. Methods 38, 84-89 (2006).